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follow-up in subsequent years following a cardiovascular event. First-year costs of
the cardiovascular events considered were: myocardial infarction (US$5,026); an-
gina(US$2378); congestive heart failure (US$3314); stroke (US$5006) and peripheral
vascular disease (US$2508). The cost of laser intervention was US$4248, while the
cost of a cataract operation was US$2916. CONCLUSIONS: Costs for treating diabe-
tes-related complications are an important driver of economic burden for DM.
Costs presented in this study provide useful inputs for further economic evalua-
tions of DM treatments in Mexico.
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OBJECTIVES: Diabetes mellitus (DM) represents a challenging problem to health-
care systems globally as it requires a high level of expenditure. In Algeria, nearly
US$264 million was spent on DM in 2010; this is expected to rise to US$461 million
by 2030. The aim of this study was to collect 2011 direct medical costs of the
management and treatment of DM-related complications from the Algerian Social
Insurance perspective.METHODS:A structured literature searchwas conducted to
search for the published costs of interest but no relevant publications were iden-
tified. Consequently, IMS collected the required costs from official sources identi-
fied using its local resources. Six groups of costs were created basedmainly on type
of complications: management costs, cardiovascular complications, renal compli-
cations, acute events, eye-disease and neuropathy/foot ulcers which were pre-
sented as first-year costs and costs in subsequent years following an event in 2011
US-dollars (1 US$72.868 AD). RESULTS: The highest first year costs were observed
in the renal complications group; renal transplantation (US$28,422), continuous
ambulatory peritoneal dialysis (US$3,901) and haemodialysis (US$3,742). High an-
nual costs were also associated with the treatment of cardiovascular complica-
tions, ranging from US$865 for first-year treatment of myocardial infarction to
US$132 for first-year treatment of peripheral vascular disease. Other first-year
costs of treating cardiovascular events were: stroke (US$282), congestive heart fail-
ure (US$244), and angina (US$395). The cost of an amputation procedure was
US$533, excluding the cost of prosthesis (US$618), with a follow-up cost of US$22.
The cost of a laser eye procedure was US$48, while the cost of a cataract operation
was US$123. CONCLUSIONS: The study identified the Social Insurance costs re-
lated to treating DM complications which may add to the financial burden on the
Algerian health care system. Data from this study may be used further to evaluate
the economic impact of DM-related treatments in Algeria.
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OBJECTIVES: Health care systems in many countries are facing a significant finan-
cial burden due to the costs incurred by treating Diabetes mellitus (DM). In Brazil,
expenditure on DM care in 2010 was estimated at US$4.3million and is expected to
rise to nearly US$7.2 million by 2030. This study aims to collect up-to-date direct
medical costs of managing and treating DM-related complications from the Brazil-
ian health care system perspective.METHODS:Most costs were obtained from the
Brazilian Ministry of Health and published studies identified through a structured
literature search. Pre-2011 costs were inflated using the Consumer Price Index.
Costs were categorised in six groups: management costs, cardiovascular compli-
cations, renal complications, acute events, eye-disease and neuropathy/foot ul-
cers. Costs were expressed in 2011 US-dollars in accordance with the average an-
nual exchange rate (1 US$1.669 BRL) and were reported as per event costs in the
first-year of the event and in subsequent years following the event. RESULTS:
First-year haemodialysis and renal transplantation costs were the highest costs
observed overall at US$14,855 and US$14,051, respectively. The highest first-year
cost of treating cardiovascular complications was that for myocardial infarction
(US$4752). Other first-year costs of treating cardiovascular complications were:
congestive heart failure (US$2,852), stroke (US$1812) and angina (US$532). The cost
of an amputation procedure was US$3771 without the cost of prosthesis (US$1584).
The cost of a laser eye operation was US$2064 and the cataract operation cost was
US$507. CONCLUSIONS: DM-related complications impose significant costs on the
Brazilian health care budget which highlights the importance of conducting eco-
nomic evaluations to assess the impact of DM-related treatments on treatment
costs and health outcomes. Costs from this study can be used to conduct such
economic evaluations which provide valuable information to decision makers in
the assessment of DM-related treatments.
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OBJECTIVES: In Kenya, diabetes prevalence is comparable toWestern countries. In
Sub-Saharan countries, the emphasis must be on prevention because theWestern
model of emphasizing treatment is unaffordable and unachievable. This study is a
cost benefit analysis (CBA) of a diabetes prevention program in rural Kenya.
METHODS: Convenience sample of adult residents from a rural county in Kenya
(Kiambu)were randomized to one of twoWTP techniques, StructuredHaggling (SH)
and Payment Card (PC). Program benefits (WTP) were collected via face-to-face
interviews using the ex-ante approach. Program costs were estimated based on
World Health Organization program cost estimation guidelines for low income
countries in Africa, and program costs tabulated in the literature (eg Haddix et al
2006), supplemented expert opinion: diabetes educators at the Kenya Diabetes
Management and Information Centre. RESULTS:WTP data was collected from 158
rural residents (70% male, 2.5% diabetic,11% own a vehicle and mean monthly
expenditures of Ksh10,933 (US2011$ 127.12). Mean annual WTP for the prevention
program was Ksh628.75 (US2011$7.30) for PC and Ksh683.97 (US2011$7.95) for SH
per respondent per year, p0.516. Mean annual cost for providing the program to
rural residents (assuming 100 clients/week) was Ksh1,228 (US2011$14). Therefore,
program cost exceeded the benefit resulting in a negative net social benefit (NSB).
CONCLUSIONS: Based onWTP (benefit) data, residents valued the diabetes preven-
tion program in rural Kenya. From a societal perspective, however, the costs for
implementing the program outweighed the benefits. The evaluated program is a
stand-alone project. Policy makers may consider a number of options that can
reduce the operating costs of the program including, implementation of the pro-
gram as part of established diabetes clinics, or administering the services to al-
ready gathered groups such as at religious functions: such an approachmay result
in a positive NSB.
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OBJECTIVES: A recent randomized, open-label, parallel group trial showed that
liraglutide is superior to sitagliptin for reduction of HbA1c. Although these findings
support the use of liraglutide as an effective GLP-1 agent to add to metformin, the
value of liraglutide needs to be quantified in the framework of a cost-effectiveness
(CE) analysis in a US setting. This current study sets out to assess the long-term CE
outcomes of liraglutide vs. sitagliptin based on treatment effects data from the
52-week trial. METHODS: The IMS CORE Diabetes Model, a non-product-specific,
validated computer simulation model that projects the long-term outcomes re-
lated to interventions for type 2 diabetes, is used for simulation over 35 years.
Patients were simulated on one of the 3 treatment options: liraglutide 1.2 mg daily,
1.8mg daily, or sitagliptin 100mg daily, each used as add-on therapy tometformin.
Incremental cost-effectiveness ratios (ICER) were generated for liraglutide 1.2 mg
versus sitagliptin and liraglutide 1.8 mg versus sitagliptin. Transition probabilities,
health state utility values and complication costs were obtained from published
sources. All outcomes were discounted at 3% per annum, and the analysis was
conducted from the perspective of a third-party payer in the US. Sensitivity anal-
yses were performed to test robustness of the base case scenario. RESULTS: For
liraglutide 1.8 mg versus sitagliptin, the ICER was $37,234 per QALY gained, while
for liraglutide 1.2mg versus sitagliptin, the ICERwas $25,742 perQALY gained. In all
sensitivity analyses including setting the HbA1c reduction to its 95% lower limit,
the ICERs remained below USD 50,000/QALY, a commonly accepted threshold in
the United States, except for the shortest time horizon of 10 years. CONCLUSIONS:
The availability of liraglutide 1.2mg and 1.8mgwith improved efficacy profiles over
sitagliptin could improve patient care, while being cost-effective treatment options
as add-on to metformin.
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OBJECTIVES: Although, safety and efficacy of exenatide BID (exenatide) and lira-
glutide for treating type 2 diabetes (T2D) has been demonstrated in trials, their
comparative economic benefits are unknown. This study examined cost offsets
and medication adherence with use of exenatide versus liraglutide in managed
care population. METHODS: A retrospective cohort analysis was conducted using
the LifeLink database, comprising adult patients with T2D who initiated exenatide
(n2383) or liraglutide (n1535) between January 1, 2010 and June 30, 2010 andwith
6months pre- andpost-index continuous eligibility. Patientswere propensity score
matched to control for on baseline differences. Medication adherence was mea-
sured using the proportion of days covered (PDC). The paired t-test andMcNemar’s
test were used to compare outcomes. RESULTS:Matched exenatide and liraglutide
cohorts (n1347 pairs) had comparable age (54 vs. 53 years), gender (55% vs. 57%
female), and comorbidities (86% vs. 86%). In the 6-month follow-up, exenatide and
liraglutide patients had similar mean total costs ($6688 vs. $7346). Significant cost
savings were observed in mean total pharmacy costs ($2925 vs. $3272, P 0.001).
There were no significant differences in mean total outpatient ($2541 vs. $3050) or
inpatient ($1222 vs. $1025) costs. Among patientswho initiated liraglutide, those on
1.8mgdoses (n638) had significantly highermean total costs than those on 1.2mg
doses (n438) ($8046 vs. $6737, P 0.043) due to higher mean total pharmacy costs
in the 1.8 mg cohort ($4017 vs. $3295, P 0.001); 35% higher mean drug cost for
liraglutide claims in the 1.8 mg cohort largely accounted for this difference ($1876
vs. $1390, P 0.001). There was no significant difference in medication adherence
between groups (mean PDC: exenatide 56% vs. liraglutide 57%). CONCLUSIONS:
Patients initiating exenatide versus liraglutide for the management of T2D had
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similarmedication adherence and total medical costs however; exenatide patients
had significantly lower total pharmacy costs.
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OBJECTIVES: To evaluate the cost-effectiveness of alternative renal screening
strategies and implications for blood pressure treatment in patients with type 1
diabetes. This required development of a discrete time simulationmodel for type 1
diabetes patients to estimate quality-adjusted life years (QALYs). METHODS: We
synthesized evidence on type 1 diabetes patients using several published sources.
The simulation model was based on eleven equations to estimate transitions be-
tween health states. Screening identified patients with impaired renal function
whom were then assigned angiotensin-converting enzyme inhibitors (ACE-I) to
lower blood pressure and improve renal function. Screening intervals were varied
from 1 year to 10 yearly intervals and compared to current UK guidelines of annual
screening. Outcomes were expressed in QALYs based on utilities of different dia-
betes complications obtained from a meta-analysis. Costs of the monitoring pro-
gram, treatment and hospitalisation from diabetes-related complications were in-
cluded. 1000 patients (mean age 15 years) were simulated for 85 years and cost-
effectiveness analyses performed. Costs and effects were discounted at standard
rates. Uncertainty surrounding these results was also calculated. RESULTS:When
comparing annual screening to biennial screening, the reduction in the number of
patients on ACE-I reduces both costs and QALYs, showing an incremental cost-
effectiveness (ICER) ratio of £9,718 per QALY. Increasing the screening interval to 5
years resulted in further reductions in both costs and QALYs, and an ICER well
within the National Institute of Health and Clinical Excellence’s (NICE) recom-
mended threshold. Sensitivity analyses showed universal treatment increased
survival rates when compared to annual screening and no treatment by an addi-
tional 4.4 and 5.5 years, respectively. CONCLUSIONS: Renal screening for people
with type 1 diabetes is cost-effective in the UK context compared to other funded
health interventions. Further research is required to determine whether universal
treatment is a policy that is worth pursuing in the long term.
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OBJECTIVES: It is currently estimated that 2 million South Africans suffer from
Type 2 Diabetes. Experts agree that the burden of diabetes is unacceptably high.
Thus access to appropriate treatment is a priority for the country. The objective of
this study was to investigate the cost effectiveness of saxagliptin (Onglyza®), a
DPP-4 inhibitor, plus metformin compared with a sulphonylurea (SU) plus met-
formin (MET) in South African patients not well controlled on metformin alone.
METHODS:Data from a 52 week clinical trial comparing saxagliptin and sulphony-
lurea in combination with metformin was used in a simulation model to estimate
long term complications in a cohort of type 2 diabetes patients. The model esti-
mates the incidence of microvascular andmacrovascular complications, diabetes-
specific mortality, all-cause mortality, and ultimately, costs and quality-adjusted
life years (QALYs) associated with the investigated treatment strategies. Costs and
QALYs were estimated for a lifetime time horizon and discounted at 5%. The per-
spective of private health care funders was used. RESULTS: Compared with SU
MET, the cost per QALY gainedwith saxagliptinMET is approximately ZAR 35,566.
Patients on saxagliptinMET gain 0.1 QALYs on average when compared to SU
MET, at an incremental cost of around ZAR 3775. The cost-effectiveness results
were robust to various sensitivity analyses. The improvement in quality of life was
associated mainly with lower incidence of hypoglycaemic events and modest re-
ductions in both macro and micro vascular complications in the cohort receiving
saxagliptin plus metformin compared with SUMET. CONCLUSIONS: This study
demonstrates that, over a patient’s lifetime, the addition of saxagliptin to met-
formin is associated with improvements in quality-adjusted life years compared
with SU in patients with type 2 diabetes. Saxagliptin treatment is a cost-effective
treatment alternative for type 2 diabetes in patients not well-controlled on met-
formin alone.
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OBJECTIVES: To evaluate the cost-effectiveness of saxagliptin plusmetformin ver-
sus sulfonylurea plus metformin in T2DM patients, who cannot achieve glycemic
goals with metformin monotherapy, in Colombia. METHODS: Cost effectiveness
analysis was performed using a discrete event simulation model with fixed time
steps (Cardiff Diabetes Model). The characteristics of the patients included in this
study and the efficacy profile for each treatment were obtained from the published
literature. The cost of medication was obtained from SISMED and Farmaprecios,
and the macro and microvascular events were based on POS tariffs, SOAT Manual
and consultationwith a local expert. The timehorizonwas 20 years and the applied
discount rate on costs and benefits was 3.5%. One-way and probabilistic sensitivity
analyses were performed for parameters and model assumptions. RESULTS: The
group treated with saxagliptin combination had fewer fatal and nonfatal events
and fewer episodes of hypoglycemia than the sulfonylurea combination popula-
tion. In both treatment groups the costs are driven by drug costs and treatment
costs associated with myocardial infarction. The incremental cost of saxagliptin
combination therapy over 20 years was US$555.552. Treatment with saxagliptin
plusmetformin resulted in a greater number of quality-adjusted life years (QALYs)
and life-years gained (LYG) than the sulfonylurea combination (9.758 vs. 9.504 and
11.786 vs. 11.758 respectively). The cost per QALY gained was US$2190. Cost-effec-
tiveness results were robust to sensitivity analysis. CONCLUSIONS: Considering
the GDP per capita in Colombia (US$6,348), our results suggest that the addition of
saxagliptin tometformin in patientswho do not achieve adequate glycemic control
withmetforminmonotherapy, is highly cost-effective compared with the addition
of sulfonylurea.
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OBJECTIVES:Analog insulin has become increasingly popular despite higher per
unit price compared to human insulin. This study evaluated the cost-effective-
ness of two premixed analog insulin preparations, compared with long-acting
analog insulin (LAAI) and pre-mixed human insulin (PHI) from the perspective
of a UK health care payer.METHODS: The CORE Diabetes Model (IMS Health) was
used to evaluate the cost-effectiveness of biphasic insulin [insulin lispro 75/25
(LM75/25) and 50/50 (LM50/50)] versus LAAI and PHI. Treatment effects were
taken directly from a recent Agency for Healthcare Research and Quality (AHRQ)
meta-analysis, while pharmacy, complication and patient management costs
were taken from published sources, expressed in 2008 pounds sterling. Future
costs and clinical benefits were discounted at 3.5% per annum. Sensitivity anal-
yses included: A1C effect, relative risk (RR) of hypoglycemia, time horizon, dis-
count rate, diabetes treatment and complication costs, and method of quality
adjusted life expectancy estimation. RESULTS: LM75/25 and LM50/50 increased
discounted quality-adjusted life expectancy (QALE) by 0.10 and 0.12 quality-
adjusted life years (QALYs), respectively, and reduced total lifetime direct med-
ical costs (LM75/25:£20,809 LAAI:£22,234; LM50/50:£20,680 LAAI:£21,292), domi-
nating LAAI. Compared to PHI, both LM75/25 and LM50/50 increased QALE (by
0.03 QALYs) and total lifetime direct medical costs (LM75/25/LM50/50:£18,499
PHI:£18,494), resulting in an incremental cost effectiveness ratio of £146/QALY
on a weighted mean A1C benefit of 0.06% in both cases. The only sensitivity
analyses in which LM75/25 and LM50/50 were not cost-effective compared to
LAAI or PHI were those in which the least favorable bound of the 95% confidence
intervals for RR of hypoglycemia or A1C difference were used. CONCLUSIONS:
Based on the findings of the AHRQ meta-analysis, and assuming a cost/QALY
threshold of £30,000/QALY, LM75/25 and LM50/50 would be considered cost-effec-
tive when compared with PHI and dominant when compared with LAAI from the
perspective of the UK health care payer.
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OBJECTIVES: Effective glycemic control can reduce the risk of serious micro- and
macrovascular complications in type 2 diabetes. However, many patients fail to
reach glycemic targets due partly to low efficacy and adverse effects of treatment
(such as hypoglycemia or weight gain). The aim of this analysis was to evaluate the
short-term cost-effectiveness of liraglutide versus sitagliptin, in terms of cost per
patient reaching a glycated hemoglobin (HbA1c) target with no hypoglycemia and
noweight gain after 52-weeks, based on a recently published trial.METHODS:Data
were taken froma randomized, controlled trial (NCT00700817) inwhich adultswith
type 2 diabetes (mean age 55 years, HbA1c 8.4%, BMI 33kg/m2) failing metformin
monotherapy were randomly allocated to receive either 1.2mg liraglutide, 1.8mg
liraglutide or 100mg sitagliptin daily in addition to metformin. For the cost-effec-
tiveness analysis, the proportion of patients achieving a clinically relevant com-
posite endpoint, defined as HbA1c7.0%, with no reported hypoglycemia and no
gain in bodyweight, were estimated using logistic regression. Costs of antidiabetes
medications were accounted based on published wholesale acquisition costs in
2011USdollars ($).RESULTS:Trial data showed that 38.9% of patients on liraglutide
1.2mg and 49.9% on liraglutide 1.8mg achieved the composite endpoint, compared
with 18.6% on sitagliptin. Overall pharmacy costs (needle costs included) were
higher on liraglutide than sitagliptin.When expressed as themean cost per patient
reaching target HbA1c with no hypoglycemia or weight gain (cost of control), costs
were notably lower on liraglutide than on sitagliptin. Annual mean costs of control
were $9,632 on liraglutide 1.2mg and $10,933 on liraglutide 1.8mg, versus $14,711 on
sitagliptin.CONCLUSIONS:Themean cost per patient achieving control, defined as
reaching HbA1c target with no hypoglycemia or weight gain, was lower with lira-
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